Amicus Therapeutics, Inc. (FOLD) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Philadelphia, PA, 미국. 현재 CEO는 Bradley L. Campbell.
FOLD 을(를) 보유 IPO 날짜 2007-05-31, 499 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $4.54B.
Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia that specializes in discovering, developing, and commercializing medicines for rare genetic diseases. The company's lead commercial product is Galafold, an oral precision medicine approved for treating adults with Fabry disease who carry amenable galactosidase alpha gene variants. Its pipeline includes AT-GAA for Pompe disease, AT-GTX-502, a gene therapy in Phase 1/2 development for CLN3 disease, and a gene therapy program targeting CDKL5 deficiency. Amicus maintains strategic collaborations with major research institutions including Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline to advance its development programs. Founded in 2002, the company is focused on addressing significant unmet medical needs in the rare disease community.
